PMID- 3154320
OWN - NLM
STAT- MEDLINE
DCOM- 19910326
LR  - 20201209
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 1
IP  - 2
DP  - 1987 Aug
TI  - A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in 
      congestive heart failure: clinical improvement during short-term treatment.
PG  - 169-75
AB  - Piperanometozine (OPC-8212) is a new, orally effective inotropic agent. To 
      evaluate the efficacy of this agent on systemic hemodynamics and clinical 
      symptoms in patients with congestive heart failure, a multicenter study was 
      performed. Thirty four patients with New York Heart Association (NYHA) functional 
      classes II to IV and initially treated with digitalis were enrolled from ten 
      centers. After a washout period of one or two weeks (placebo period), digitalis 
      was replaced by piperanometozine (30 or 60 mg/day) for four weeks, while other 
      drugs were continued. Clinical symptoms, routine physical findings, 
      electrocardiogram, chest roentgenogram, echocardiogram, exercise tolerance time, 
      and routine laboratory data were obtained in 34 patients. Four patients were 
      withdrawn from the study before completion. After the withdrawal of digitalis, 
      heart rate was increased and ejection fraction was decreased. Exercise tolerance 
      time was increased while other parameters were unchanged. At the end of the 
      treatment period with piperanometozine, ejection fraction significantly (p less 
      than 0.05) increased with a decrease in LV end-systolic volume (p less than 
      0.05), whereas heart rate and blood pressure remained unchanged. Systolic blood 
      pressure/LV end-systolic volume (P/V index) tended to decrease after the 
      withdrawal of digitalis and increase during piperanometozine therapy. Exercise 
      tolerance time was further increased (p less than 0.01) and NYHA functional class 
      was improved in 11 patients, whereas it worsened in only one patient. No major 
      adverse effects were observed. These results indicate that a short-term therapy 
      of oral piperanometozine restored the depressed cardiac performance of the heart 
      and improved clinical symptoms in patients with congestive heart failure. Thus, 
      this promising agent deserves further clinical study in long-term trials.
FAU - Inoue, M
AU  - Inoue M
AD  - First Department of Internal Medicine, Osaka University, School of Medicine, 
      Japan.
FAU - Hori, M
AU  - Hori M
FAU - Yasuda, H
AU  - Yasuda H
FAU - Takishima, T
AU  - Takishima T
FAU - Sugimoto, T
AU  - Sugimoto T
FAU - Sasayama, S
AU  - Sasayama S
FAU - Sakurai, T
AU  - Sakurai T
FAU - Nonogi, H
AU  - Nonogi H
FAU - Kodama, K
AU  - Kodama K
FAU - Kusukawa, R
AU  - Kusukawa R
AU  - et al.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Pyrazines)
RN  - 0 (Quinolines)
RN  - 5COW40EV8M (vesnarinone)
SB  - IM
MH  - Aged
MH  - Cardiotonic Agents/adverse effects/*therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrazines
MH  - Quinolines/adverse effects/*therapeutic use
EDAT- 1987/08/01 00:00
MHDA- 1987/08/01 00:01
CRDT- 1987/08/01 00:00
PHST- 1987/08/01 00:00 [pubmed]
PHST- 1987/08/01 00:01 [medline]
PHST- 1987/08/01 00:00 [entrez]
AID - 10.1007/BF02125470 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1987 Aug;1(2):169-75. doi: 10.1007/BF02125470.